VACCINE THERAPY FOR MULTIPLE MYELOMA ALLOGENEIC DENDRITIC CELLS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项I/II期研究将初步评估30名多发性骨髓瘤患者接种同种异体树突状细胞独特型KLH型疫苗的可行性和安全性。 这项研究的第一阶段将招募15名符合资格标准的患者。如果在第一个队列中有足够数量的患者完成疫苗接种，并且急性移植物抗宿主病(GVHD)的发病率没有增加，那么将再招募15名患者完成研究的第二阶段。 至少1x106个同种异体树突状细胞冲击自体独特型-KLH蛋白将在1cc内注射，并在随后每月接种一次的五次疫苗中每一次皮内注射。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This phase I/II study will evaluate primarily the feasibility and safety in thirty (30) patients with multiple myeloma who will be vaccinated with allogeneic dendritic cell autologous idiotype-KLH vaccine. Stage 1 of the study will enroll 15 patients who meet eligibility criteria. If a sufficient number of patients complete vaccination in the first cohort and there is no increase incidence of Acute Graft versus Host Disease (GVHD), then an additional 15 patients will be enrolled to complete stage 2 of the study. A minimum of 1X106 allogeneic dendritic cells pulsed with autologous idiotype-KLH protein will be given in 1cc and delivered intradermally in each of five subsequent vaccinations given on a once monthly schedule.